Binhui Biopharmaceutical

Focus: Binhui Biopharmaceutical is a China-based gene therapy company specializing in viral vectors, nucleic acids, cell line development, and antibodies with a focus on oncology and infectious disease.

Gene Therapy

Profile data last refreshed 8h ago · AI intelligence enriched 2w ago

Open Jobs

About Binhui Biopharmaceutical

AI assessmentNot Hiring

No open roles listed right now. Follow Binhui Biopharmaceutical to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Virus Activated Killer immune Cells

Malignant Pleural Effusion

Phase 1

Clinical Trials (1)

NCT05565014Safety and Efficacy Study of Virus Activated Killer Immune Cells (VAK) for Malignant Pleural and Peritoneal Effusion

Phase 1

Help build intelligence for Binhui Biopharmaceutical

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Diversified pipeline with 16 active clinical trials across multiple tumor types and modalities, including promising Phase 3 melanoma program (OH2)
Specialized expertise in viral vector and gene therapy platforms—rare technical skill-building in emerging modalities with limited competition
China-based operation with headquarters in Wuhan provides access to growing Asian biotech ecosystem and regulatory pathways

Watch Out For

Zero active job openings reported, suggesting minimal near-term hiring and limited career mobility
Lack of public financial data (revenue, funding, employee count) creates transparency risk and makes compensation/stability assessment impossible
Pipeline heavily concentrated on early-stage programs (13 Phase 1, 3 Phase 2, only 1 Phase 3); no approved products or revenue-generating commercialization activities

Generated by Claude from Binhui Biopharmaceutical's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

BS006 Injection

Solid Tumor

Phase 1

Clinical Trials (1)

NCT05938296oHSV2-PD-L1/CD3-BsAb Administered Via Intratumoral Injection

Phase 1

the recombinant SARS-CoV-2 S-Trimer vaccine/inactivated SARS-CoV-2 vaccine

COVID-19

Phase 1

Clinical Trials (1)

NCT05716347Clinical Trial of Safety and Immunogenicity of Recombinant SARS-CoV-2 S-Trimer Vaccine (CHO Cells) as Booster Vaccination in Populations Aged 18 to 59 Years

Phase 1

OH2 Injection

Solid Tumor

Phase 1

Clinical Trials (1)

NCT05954091OH2 Administered by Intratumoral Injection

Phase 1

OH2 injection

Advanced Liver Cancer

Phase 1

Clinical Trials (1)

NCT05698459OH2 Oncolytic Viral Therapy Via Transcatheter Intraarterial Infusion in Patients with Advanced Liver Cancer